"Ad>120 msec" or "LP2<-3.5 ,uV" should have been written: "predictive accuracy. " We are also aware of the importance of the prevalence in the general population to draw a positive or negative value as a diagnostic tool. In this matter, we agree with them. However, we chose as our target a hospital population mainly to differentiate the disease from the normal but not the general population, which makes it possible to diagnose it based on the prevalence of the disease, because it is very difficult to detect patients with paroxysmal atrial fibrillation during sinus rhythm.
Another study on the prevalence may be needed to screen the general population. However, the prevalence itself of paroxysmal atrial fibrillation seems very difficult to obtain, especially in the case of asymptomatic paroxysmal atrial fibrillation or even symptomatic paroxysmal atrial fibrillation without stroke. Consequently, from the present study, the sensitivity and specificity are at least valid because these do not depend on the prevalence. Also, the reason of having presented the predictive accuracy is that the positive predictive value is more heavily affected by the prevalence than the predictive accuracy.
The meaning of the screening is "the presumptive identification of an unrecognized disease or defect by the application of tests which can be applied rapidly" (cited from Reference 2). "A screening test is not intended to be diagnostic".2 However, they appear to think that a positive result of the test indicates a need of anticoagulant therapy for prevention of stroke. In fact, we are now using this method in clinical situations as a screening test to do further examination (but not as a diagnostic tool) in patients suffering from paroxysmal palpitation.
As they stated in their letter, atrial fibrillation, whether it is chronic or paroxysmal, is a potential risk of systemic thromboembolism. 34 We previously demonstrated5 that atrial fibrillation itself may be more important than factors predisposing to atrial fibrillation in the development of intracardiovascular clotting, which was compatible with the results in this study in terms of independence of the presence of underlying organic heart disease. Therefore, such a screening test is thought to be more important in patients without organic heart disease who visit a hospital only because of palpitation or chest discomfort. 
Life Expectancy and Coronary Artery Disease
Tsevat et a1l have reported that elimination of mortality from coronary artery disease (CHD) from the U.S. population would increase average life expectancy at 35 years of age by 3.1 years for males and 3.3 years for females. These findings are of significant interest, particularly in the public arena, in that they provide some basis for future decisions affecting public health, including patterns and trends of funding for various areas of biomedical research. Thus, this research effort has received broad exposure in the press and other public media.
However, the main conclusion of the study by Tsevat et all is neither unexpected nor novel. Nearly 30 years ago, Robert R. Kohn2,3 utilized curves for age-specific death rates to estimate the beneficial increase in human life span if deaths from several selected diseases were to be eliminated. Kohn concluded that elimination of all deaths from arteriosclerosis (as arteriosclerotic heart disease, most vascular diseases of the central nervous system, and the majority of chronic renal diseases) would result in an increase in life expectancy at birth of approximately 7 years. This value is well within the range generated by others who model life extension following modification of risk factors for CHD, as discussed by Tsevat et al.' Because deaths from CHD between birth and 35 years are of little concern in terms of public health, Kohn' s estimate is remarkedly similar to the benefit generated by Tsevat et all when adjusted for the well-discussed decline in mortality from CHD that has occurred over the past 25 years. Therefore, it is clearly evident to us that Kohn should be credited for his pioneering studies in this area of endeavor carried out a full quarter of a century before present efforts.
Malcolm B. Baird, PhD Harold R. Massie, PhD Jane L. Hough, PhD Masonic Medical Research Laboratory Utica, N.Y.
Reply
We appreciate the comment by Drs. Baird, Massie, and Hough, who indicated that the findings in our report1 were of significant interest. We also appreciate the additional citation of Dr. Kohn's 1963 article. In our article, we cited several previous reports that were consistent with ours. Since our article was submitted, an analysis by Olshansky and colleagues2 corroborated our findings by projecting that eliminating ischemic heart disease would increase life expectancy at birth by 3.0 years for females and 3.55 years for males. It should be noted, however, that the focus of our paper was on gains in life expectancy from risk factor modification rather than from eliminating coronary heart disease (CHD) per se (an impossible goal).
Interpreting Data From the MRFIT The MRFIT (Multiple Risk Factor Intervention Trial) Research Group has presented us with very important data on long-term efficacy of structured treatment of the three major risk factors: smoking, hypercholesterolemia, and hypertension. Unfortunately, the interpretation of the results is dubious and the findings leave room for different conclusions.
The conclusion "These 10.5-year mortality data support the inference that a multifactorial intervention program such as that used in the MRFIT has long-term beneficial effects for persons with hypertension" appears to represent an overinterpretation of the results. After the 10.5 -year multifactorial intervention effort in over 4,000 hypertensive men (of which 55% smoked and 50% had serum cholesterol 2>250 mg/dl; these men were not entirely low-risk hypertensives), neither total mortality nor coronary heart disease (CHD) mortality were significantly lower in the SI group than in the usual care (UC) group. The small, insignificant difference in CHD deaths (n=21) corresponded to an absolute difference after more than 10 years of intense, multifactorial treatment of 0.5%. The corresponding absolute difference in total mortality was just short of 1 %. This should have been said instead of trying to give the reader the impression that differences did exist.
The results in those with untreated diastolic blood pressure >100 mm Hg at entry support all other data that hypertensives with these levels benefit markedly from multifactorial intervention. However, the larger group by far with untreated diastolic blood pressure 90-99 mm Hg and those already on treatment at entry seemed to have no or very little benefit of the multifactorial intervention program in the SI group compared with UC. There were 62 fewer CHD deaths in the SI group, corresponding to a 0.2% lower absolute risk for having a CHD event in that group. That death from all causes was 0.65% higher in the SI group was not discussed. A proper conclusion would be that the majority of hypertensive men with a diastolic blood pressure below 100 mm Hg had no benefit of 10.5 years' intensive MRFIT intervention against blood pressure, smoking, and high serum cholesterol compared with the usual available care in the United States.
The authors comment on the finding that in the diastolic blood pressure strata 90-99 mm Hg, the initial unfavorable outcome in the SI group regarding CHD deaths and deaths from all causes with prolonged follow-up has changed toward a more positive trend. As a matter of fact, the major part of the text deals with various subgroup analyses and attempts to explain this-as it seems-unexpected finding. The authors discuss three possible explanations for this favorable trend but seem to have overlooked the most obvious one. If intensive blood pressure reduction in the SI group (irrespective of type of drug) increased the risk of cardiovascular deaths, a number of high-risk individuals have died in this group before the dosage of the diuretic drug in the SI group was lowered. One can assume that the UC group was less vigorously treated. Thus, these high-risk individuals remained in the UC group and were hence 'at risk" for a fatal event during the posttrial follow-up.
The J-shaped curve' 2 has been debated during several years3 4 and I have previously urged5 large trials to present the results regarding achieved blood pressure level. The Hypertension Detection and Follow-up Program (HDFP)6 has done so and shown a J-shaped relation between change in blood pressure and CHD events. It is surprising that the authors of the MRFIT report have not even commented on the possibility of a J-shaped phenomenon behind their long-term results.
Professor Berglund challenges our interpretation of results and the conclusions in our abstract concerning the benefit of intervention on 10.5-year mortality for hypertensive participants in the Multiple Risk Factor Intervention Trial (MRFIT).' Before addressing the three specific criticisms, we reiterate our conclusion as stated in the last paragraph of the report:
"These findings are generally concordant with those of HDFP2 and with results of recent meta-analyses.3-6 They indicate that for hypertensive persons pharmacological therapy combined with life-style counseling to improve eating habits, lower serum cholesterol, and achieve smoking cessation may be broadly beneficial in the long term."1 Thus, MRFIT is but a part of a large body of evidence that indicates that treatment of hypertension is efficacious in preventing stroke and other cardiovascular disease.2-6 The recent report of the Systolic Hypertension in the Elderly Program (SHEP trial) indicates that treatment is also beneficial in older persons.7 While questions remain on optimal antihypertensive therapy, there is little doubt that treatment has substantial benefit in preventing cardiovascular morbidity and mortality over a broad age range in men and women.
In Professor Berglund's first criticism, he notes that there was not a statistically significant lower rate in the special intervention (SI) group compared with the usual care (UC) group for either coronary heart disease (CHD) or total mortality. This observation is clearly evident from the text, tables, and abstract. It is our
